Sivelestat, a small-molecule neutrophil elastase (NE) inhibitor, is approved in Japan and South Korea for ARDS associated with systemic inflammatory response syndrome (SIRS) and has demonstrated clinical efficacy. Here, ELANE is linked to systemic inflammatory response syndrome.